Michael J. Wick

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

Toshio Shimizu, Anthony W. Tolcher, Kyriakos P. Papadopoulos et al. · Clinical Cancer Research · 2012 · 429 citations

A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer

Manuel Hidalgo, Elizabeth Bruckheimer, N.V. Rajeshkumar et al. · Molecular Cancer Therapeutics · 2011 · 400 citations · Full text

An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma

Yotam Drier, Matthew J. Cotton, Kaylyn E. Williamson et al. · Nature Genetics · 2016 · 296 citations · Full text

Malignant Disease, Oncogenic Agent, Medicine +8

Activating <i>NOTCH1</i> Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors

Renata Ferrarotto, Yoshitsugu Mitani, Lixia Diao et al. · Journal of Clinical Oncology · 2017 · 237 citations · Full text

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)

Ursula A. Germann, Brinley F. Furey, William Markland et al. · Molecular Cancer Therapeutics · 2017 · 225 citations